Skip to main
BNTX
BNTX logo

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 33%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's oncology pipeline shows strong potential, particularly with the upcoming Phase 3 DYNASTY-Breast02 trial for BNT323, which targets HR+, HER2-low metastatic breast cancer, indicating promising advancements in individualized immunotherapy. Additionally, the development of the LP.8.1-adapted monovalent COVID-19 vaccine, which demonstrates enhanced immune responses against various SARS-CoV-2 sublineages, reinforces the company's commitment to addressing emerging infectious diseases. These elements underscore BioNTech's innovative approach and expanding drug portfolio, contributing to a broadly favorable outlook for the company's financial trajectory.

Bears say

The analysis indicates a negative outlook on BioNTech's stock due to several significant risks including potential negative data from key programs within its oncology pipeline, such as BNT122 and BNT211, as well as a slower-than-expected market uptake for its products. Additionally, challenges associated with advancing other development programs timely, along with regulatory and commercial risks, contribute to a concerning operational environment. Furthermore, the impact of changing dynamics in the COVID-19 vaccine landscape, particularly related to a more restrictive regulatory environment in the U.S., may distract investors from focusing on BioNTech's oncology initiatives.

BioNTech SE (BNTX) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 12 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $136.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $136.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.